(Q37766688)

22 August 2017

1 reference

title

Platelet biology and implications for antiplatelet therapy in atherothrombotic disease (English)

1 reference

22 August 2017

1

Gilles Montalescot

1 reference

22 August 2017

publication date

21 June 2010

1 reference

Clinical and Applied Thrombosis-Hemostasis

22 August 2017

published in

1 reference

22 August 2017

volume

17

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

371-380

1 reference

Thrombin and platelet activation

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelet-collagen interaction: is GPVI the central receptor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Activation of platelet function through G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Protease-activated receptors in hemostasis, thrombosis and vascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Fibrinogen and fibrin: scaffold proteins in hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

A revised model of platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Angioscopic Evaluation of Coronary-Artery Thrombi in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Central role of the P2Y12 receptor in platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelets: physiology and biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Cloning and characterization of human protease-activated receptor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Protease activated receptors: clinical relevance to hemostasis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelets in inflammation and atherogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelets: inflammatory firebugs of vascular walls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelets as immune cells: bridging inflammation and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Aspirin as an antiplatelet drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Antithrombotic therapy in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

21 January 2018

New P2Y(12) inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029610373366

21 January 2018

Identifiers

DOI

10.1177/1076029610373366

1 reference

22 August 2017

1 reference